The Effect of GnRH Analogues for Pituitary Suppression on Ovarian Response in Repeated Ovarian Stimulation Cycles

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2012 Feb 2

PMID 22295031

Citations 3

Authors

Mario Cavagna

Daniela Paes de Almeida Ferreira Braga

Fabio Biaggioni Lopes

Rita de Cassia Savio Figueira

Assumpto Iaconelli Jr

Edson Borges Jr

Affiliations

Soon will be listed here.

Abstract

Introduction: Ovarian stimulation is employed in assisted reproduction techniques in order to obtain as many oocytes as possible. The early rise in oestradiol levels may lead to the premature end of the respective cycle. In order to avoid such an effect, pituitary suppression has been employed. The aim of this study was to evaluate whether maintenance or replacement of the type of GnRH analogue (i.e., agonist or antagonist) employed for pituitary suppression in the consecutive intracytoplasmic sperm injection (ICSI) cycle would negatively influence oocyte quality and ICSI outcome.

Material And Methods: A retrospective observational study was conducted including 181 women with primary infertility. Patients were divided into four different groups according to the GnRH analogue used for pituitary suppression in the first and consecutive cycle.

Results: When a GnRH agonist was employed for pituitary suppression in the first cycle, the consecutive cycle showed comparable outcomes when performed with either a GnRH agonist or a GnRH antagonist. When the first cycle was performed with a GnRH antagonist, the use of the GnRH agonist in the successive cycle led to an increased number of oocytes retrieved (7.5% vs. 10.3%, p = 0.032) and the production of a higher number of embryos (4.5% vs. 6.3%, p = 0.036).

Conclusions: When the first cycle is carried out with a GnRH antagonist, the use of a GnRH agonist in the successive cycle would lead to increased numbers of oocytes collected and embryos produced.

Citing Articles

Effect of GnRH analogues for pituitary suppression on oocyte morphology in repeated ovarian stimulation cycles.

Zanetti B, Braga D, Setti A, Iaconelli Jr A, Borges Jr E JBRA Assist Reprod. 2019; 24(1):24-29.

PMID: 31436072 PMC: 6993161. DOI: 10.5935/1518-0557.20190050.

Comparison between cycles of the same patients when using recombinant luteinizing hormone + recombinant follicle stimulating hormone (rFSH), human menopausal gonadotropin + rFSH and rFSH only.

Tayyar A, Kahraman S Arch Med Sci. 2019; 15(3):673-679.

PMID: 31110533 PMC: 6524176. DOI: 10.5114/aoms.2017.72408.

Comparisons of the effects of long-acting and short-acting GnRH agonists on embryo quality, endometrial thickness and pregnancy rate in human in vitro fertilization.

Mao G, Feng Z, He Y, Huang Y Arch Med Sci. 2014; 10(1):161-6.

PMID: 24701229 PMC: 3953985. DOI: 10.5114/aoms.2014.40743.

References

Caligara C, Navarro J, Vargas G, Simon C, Pellicer A, Remohi J . The effect of repeated controlled ovarian stimulation in donors. Hum Reprod. 2001; 16(11):2320-3. DOI: 10.1093/humrep/16.11.2320. View

Ludwig M, Katalinic A, Diedrich K . Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 2002; 265(4):175-82. DOI: 10.1007/s00404-001-0267-2. View

Albano C, Smitz J, Camus M, Riethmuller-Winzen H, VAN Steirteghem A, Devroey P . Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997; 67(5):917-22. DOI: 10.1016/s0015-0282(97)81407-0. View

Hernandez E . Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2000; 15(6):1211-6. DOI: 10.1093/humrep/15.6.1211. View

Giampietro F, Sancilio S, Tiboni G, Rana R, Di Pietro R . Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist. Fertil Steril. 2006; 85(2):412-9. DOI: 10.1016/j.fertnstert.2005.08.020. View

Kolibianakis E, Collins J, Tarlatzis B, Devroey P, Diedrich K, Griesinger G . Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006; 12(6):651-71. DOI: 10.1093/humupd/dml038. View

Moraloglu O, Kilic S, Karayalcin R, Yuksel B, Tasdemir N, Isik A . Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients. Adv Ther. 2008; 25(3):266-73. DOI: 10.1007/s12325-008-0028-8. View

Kolibianakis E, Zikopoulos K, Smitz J, Camus M, Tournaye H, van Steirteghem A . Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod. 2004; 19(7):1525-9. DOI: 10.1093/humrep/deh272. View

Lindheim S, Morales A . GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod. 2003; 18(10):2048-51. DOI: 10.1093/humrep/deg407. View

10.

Al-Inany H, Abou-Setta A, Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007; 14(5):640-9. DOI: 10.1016/s1472-6483(10)61059-0. View

11.

Baruffi R, Mauri A, Petersen C, Felipe V, Martins A, Cornicelli J . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online. 2007; 14(1):14-25. DOI: 10.1016/s1472-6483(10)60758-4. View

12.

Rivier J, Porter J, Hoeger C, Theobald P, Craig A, Dykert J . Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. J Med Chem. 1992; 35(23):4270-8. DOI: 10.1021/jm00101a003. View

13.

Huirne J, Lambalk C . Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001; 358(9295):1793-803. DOI: 10.1016/S0140-6736(01)06797-6. View

14.

de Boer E, Tonkelaar I, Burger C, Looman C, van Leeuwen F, Te Velde E . The number of retrieved oocytes does not decrease during consecutive gonadotrophin-stimulated IVF cycles. Hum Reprod. 2004; 19(4):899-904. DOI: 10.1093/humrep/deh178. View

15.

Kolibianakis E, Osmanagaoglu K, Camus M, Tournaye H, Van Steirteghem A, Devroey P . Effect of repeated assisted reproductive technology cycles on ovarian response. Fertil Steril. 2002; 77(5):967-70. DOI: 10.1016/s0015-0282(02)02975-8. View

16.

Hoveyda F, Engmann L, Steele J, Lopez Bernal A, Barlow D . Ovarian response in three consecutive in vitro fertilization cycles. Fertil Steril. 2002; 77(4):706-10. DOI: 10.1016/s0015-0282(01)03237-x. View

17.

Wei A, Mijal K, Christianson M, Schouweiler C, Lindheim S . Comparison of GnRH antagonists and flareup GnRH agonists in donor oocyte cycles. J Reprod Med. 2008; 53(3):147-50. View

18.

Schally A . Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999; 20(10):1247-62. DOI: 10.1016/s0196-9781(99)00130-8. View

19.

Gong J, Campbell B, Bramley T, Gutierrez C, Peters A, Webb R . Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist. Biol Reprod. 1996; 55(1):68-74. DOI: 10.1095/biolreprod55.1.68. View

20.

Docchio M, Fordyce G, Whyte T, Aspden W, Trigg T . Reproductive responses of cattle to GnRH agonists. Anim Reprod Sci. 2000; 60-61:433-42. DOI: 10.1016/s0378-4320(00)00078-6. View